TransCode Therapeutics, Inc. (RNAZ)
NASDAQ: RNAZ · Real-Time Price · USD
0.515
+0.035 (7.29%)
At close: Nov 4, 2024, 4:00 PM
0.510
-0.005 (-0.97%)
After-hours: Nov 4, 2024, 7:51 PM EST
TransCode Therapeutics Employees
TransCode Therapeutics had 10 employees as of December 31, 2023. The number of employees decreased by 9 or -47.37% compared to the previous year.
Employees
10
Change (1Y)
-9
Growth (1Y)
-47.37%
Revenue / Employee
n/a
Profits / Employee
-$1,790,514
Market Cap
8.89M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 10 | -9 | -47.37% |
| Dec 31, 2022 | 19 | 10 | 111.11% |
| Dec 31, 2021 | 9 | 3 | 50.00% |
| Dec 31, 2020 | 6 | 0 | - |
| Dec 31, 2019 | 6 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| NeuroMetrix | 26 |
| BioCardia | 20 |
| Plus Therapeutics | 20 |
| ABVC BioPharma | 19 |
| Virax Biolabs Group | 17 |
| Quantum BioPharma | 17 |
| Soligenix | 15 |
| Cardio Diagnostics Holdings | 9 |
RNAZ News
- 6 weeks ago - TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate - GlobeNewsWire
- 2 months ago - TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate - GlobeNewsWire
- 3 months ago - TransCode Therapeutics, Inc. Announces Closing of Public Offering - GlobeNewsWire
- 3 months ago - TransCode Therapeutics, Inc. Announces Pricing of Public Offering - GlobeNewsWire
- 3 months ago - TransCode Therapeutics, Inc. Announces Proposed Public Offering of Common Stock - GlobeNewsWire
- 5 months ago - Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements - GlobeNewsWire
- 5 months ago - TransCode Therapeutics Reports Positive Data from First-in-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138 - GlobeNewsWire
- 6 months ago - TransCode Therapeutics Open Letter to Shareholders - GlobeNewsWire